Introduction {#S1}
============

The placenta is a fetal organ tightly interacting with maternal blood vessels to nourish and protect the fetus ([@B63]). Placental infections by pathogens are major causes of disease and represent a substantial source of human morbidity and mortality. The placenta is composed of villi that float in maternal blood and organize the exchange of substances between the mother and fetus. At this interface bacteria and viruses may enter the placenta and be transmitted to the fetus. Thus, the placenta is an important transmission site for viral and bacterial infections, and therefore it is conceivable that this organ evolved antiviral and antibacterial innate immune defense mechanisms that prevent or restrict diaplacental pathogen transmission. Indeed, only relatively few pathogens are capable of placental and fetal infections in humans ([@B63]). For example, most viral dia-placental transmissions are caused by Cytomegalovirus, Lymphocytic choriomeningitis virus, Parvovirus B19, Rubella Virus and Varicella zoster virus ([@B63]), but generally the frequencies are low. More recently, it has also been shown that Zika virus (ZIKV) may cross the placenta and infect the fetus which may result in severe developmental defects of the fetus ([@B76]). However, for the majority of viral pathogens the placenta represents an impenetrable barrier ([@B63]). For example, Herpes simplex viruses (HSV) -1 and -2 have infected billions of people. In the US, neonatal infection with HSV occurs in 1 out of every 3200--10,000 live births and is associated with serious morbidity and mortality, and leaves many survivors with permanent sequelae ([@B10]; [@B45]; [@B64]; [@B24]). Interestingly, most congenital HSV infections are transmitted during delivery whereas reports on transplacental transmission and fetal infection are extremely rare ([@B35]), despite a relatively high prevalence of up to 9% of HSV-2 DNA in placental tissue samples ([@B22]). Likewise, as part of the innate immune system, the placenta plays an important role in prevention of bacterial infection during pregnancy ([@B51]). Trophoblast cells carry toll-like receptors and thus are able to recognize bacteria via pattern recognition receptors to elicit an immune response ([@B1]). Failure to prevent bacterial infection during pregnancy may result in the termination of pregnancy and preterm delivery. While bacterial infections have clearly been implicated as one of the most important reason for preterm deliveries, the specific bacterial species that are responsible remain elusive. Nevertheless, this situation underlines the importance of an intact placental barrier. The potent barrier function that prevents dia-placental transmission of pathogens is likely due to a lack of intercellular junctions of the syncytiotrophoblast comprising most of the maternofetal interface and an environment rich in innate immune defense molecules ([@B63]).

One part of the innate immune response consists of antimicrobial peptides (AMPs) that are constantly expressed or released upon TLR stimulation ([@B28]). We have previously shown that peptide libraries generated from human body fluids are an excellent source for the discovery of novel AMPs with antibacterial and antiviral activity ([@B55]; [@B8]). Such peptide libraries are generated from pooled body fluids by chromatographic means and typically consist of 100--400 peptide fractions that contain all peptides and small proteins of the respective source material in a lyophilized and concentrated form. Screening these libraries for antibacterial fractions and subsequent purification of the bioactive peptides allowed to identify, e.g., the first human β-defensin hBD-1 ([@B6]), antibacterial peptides LEAP-1 and 2 ([@B36]; [@B37]), or Casein k(63--117) ([@B42]). Using cell-based viral infection assays, we also discovered endogenous modulators of HIV-1 infection, such as a novel chemokine ligand of CCR5 that blocks HIV infection ([@B13]; [@B56]), and a fragment of antitrypsin that inhibits HIV entry and has been successfully tested in a phase I/II clinical trial ([@B54]; [@B25]). More recently, it led to the discovery of an endogenous CXCR4 antagonist that blocks CXCR4-tropic HIV infection ([@B78]). Moreover, screening a semen derived peptide library identified amyloid-forming peptides as enhancers of HIV-1 infection ([@B53]; [@B2]; [@B65]) and antibacterial agents ([@B20]). Thus, the concept of isolating novel AMPs from body fluids resulted in the identification of peptides that inhibited bacterial and viral infections by novel and unexpected mechanisms. Here, we sought to adapt this technology and generated a peptide library from human placenta to identify endogenous inhibitors that may restrict HSV-2 infection and bacterial pathogens.

Materials and Methods {#S2}
=====================

Generation of Peptide Library From Placenta {#S2.SS1}
-------------------------------------------

Ten kilograms of human placenta were obtained from healthy individuals in a maternity ward of a local hospital and processed immediately after delivery. This study was approved by the Ethics Committee of Ulm University (file number 90/17). All subjects gave written informed consent in accordance with the Declaration of Helsinki. First, the organs were homogenized and peptides and small proteins extracted by an ice-cold acetic acid extraction procedure. Thereafter, the obtained peptides and proteins were separated by an ultrafiltration step (cut-off: 50 kDa). The resulting peptides were then separated in a first dimension by means of their isoelectric point using cation exchange chromatography resulting in pH pool fractions 1--6. Each pH pool was then further separated in a second dimension by peptide hydrophobicity using reversed phase chromatography resulting in a total of 250 fractions as described in detail before ([@B42], [@B41]).

Screening the Placenta Library for Inhibitors of HSV-2 Infection {#S2.SS2}
----------------------------------------------------------------

ELVIS^TM^ cells are genetically engineered baby hamster kidney cells that encode a lacZ gene, which is expressed upon infection via the viral transactivator ICP10 (Enzyme-Linked Virus-Inducible System -- ELVIS^TM^) ([@B61]). 5,000 ELVIS cells were seeded into 96-well plates and mixed with 10 μl of the reconstituted fractions of the placenta library. After 10 min, cells were infected with a clinical HSV-2 isolate ([@B38]) and infection was determined 2 days later by detecting the β-galactosidase activity in cellular lysates using the Gal-Screen β-Galactosidase Reporter Gene Assay System for Mammalian Cells (Thermo Fisher Scientific) and the Orion II microplate luminometer (Berthold, Bad Wildbad, Germany). All values represent reporter gene activities derived from triplicates minus background activities derived from uninfected cells. Triplicates are expressed as mean ± standard error derived from two independent experiments. All experiments with infectious viruses were performed in a BSL3^∗∗^ laboratory in accordance with biosafety guidelines by Ulm University Hospital.

Mass Spectrometry {#S2.SS3}
-----------------

MALDI TOF MS (Matrix-assisted laser desorption/ionization time of flight mass spectrometry) was carried out using a LaserTec RBT II (PerSeptive Biosystems, Framingham, MA, United States) as described in detail earlier ([@B71]). The instrument is equipped with a 1.2 m flight tube and a 337 nm nitrogen laser. Positive ions are accelerated at 30 kV and laser shots are automatically accumulated per sample. Alpha-Cyano-4-hydroxy-cinnamic acid (CHC, Sigma--Aldrich, Deisenhofen, Germany) was used as matrix. Accuracy of mass measurement was 0.5%. Electrospray MS was carried out on an LCQ ion trap mass spectrometer (Finnigan/Thermo Fisher Scientific, Bonn, Germany) with an electrospray interface (ESI--MS) as described previously ([@B31]).

Peptide Synthesis {#S2.SS4}
-----------------

Native HBB(112--147) was isolated in large amounts from human placenta. Synthetic HBB(112--147) was produced using conventional solid phase Fmoc chemistry and a Liberty blue microwave peptide synthesizer (CEM corporation, Matthews, NC, United States). The synthetic peptide showed identical chromatographic and mass spectrometric properties compared to the native peptide (purity \> 95%).

Effect of HBB(112--147) on HSV-1 and HSV-2 Infection {#S2.SS5}
----------------------------------------------------

5,000 ELVIS cells were seeded the day before into 96-well plates. Cells were incubated with 0--1000 μg/ml of HBB(112--147) for 30 min at 37°C in triplicates prior infection with clinical isolates of HSV-1 or HSV-2. Infection rates were determined 1 or 2 day(s) later as described above. For mechanistic experiments or comparative analyses ([Figures 1D](#F1){ref-type="fig"}, [2B](#F2){ref-type="fig"}) the HSV-2 strain 333 was used.

![Identification of a C-terminal fragment of hemoglobin as HSV-2 inhibitor in a placenta-derived peptide library. **(A)** Fractions 1--39 of pH pool 4 of the placenta library were added to ELVIS cells and subsequently infected with HSV-2. Infection rates were determined 2 days later by quantifying β-galactosidase activities in cellular lysates. **(B)** MALDI-MS (left) and ESI-MS (right) spectra of fraction 19. The peaks correspond to HBB(112--147). **(C)** HBB(112--147) purified from placenta and chemically synthesized peptide inhibit HSV-2 infection. Peptides were added at indicated concentrations to ELVIS cells, and cells were infected with a clinical HSV-2 isolate. Infection rates were determined 2 days later by quantifying β-galactosidase activities in cellular lysates. **(D)** Activity of HBB(112--147) against a lab strain of HSV-2 (333) and a clinical, highly ACV-resistant isolate. Peptides were added to ELVIS cells at indicated concentrations and cells were infected after 30 min incubation. Infection rates were determined 24 hpi by quantifying β-galactosidase activity.](fmicb-11-00508-g001){#F1}

![The hemoglobin fragment blocks an early step in the HSV-2 life cycle. **(A)** Indicated concentrations of HBB(112--147) were added to cells and incubated for 30 min. Thereafter, cells were either infected directly with HSV-2 (cell treatment) or washed, supplemented with fresh medium and then infected (wash). Additionally, virus was first exposed to HBB(112--147) for 3 h at indicated concentrations, and then these mixtures were used to infect cells (resulting in a 20-fold dilution of the inoculum). Infection rates were determined 2 days later by quantifying β-galactosidase activities in cellular lysates. Shown are average values derived from two experiments each performed in quadruplicates +SD. **(B)** In order to determine which stage of infection HBB(112--147) interferes with, peptide at indicated concentrations was either added to cells directly prior to infection, pre-incubated for 30 min on cells at 37°C, added 2 h post-infection (with removal of virus and addition of fresh medium), or added after overnight infection (16 hpi). Infection was evaluated by quantifying β-galactosidase activities in cellular lysates 24 hpi. Shown are average values derived from one experiment in triplicates +SD.](fmicb-11-00508-g002){#F2}

Effect of HBB(112--147) on Zika Virus Infection {#S2.SS6}
-----------------------------------------------

Virus stocks of ZIKV MR766, a ZIKV strain isolated from a sentinel rhesus macaque in 1947 ([@B14]) were generated by infecting Vero E6 cells. After 3--5 days the virus was collected by centrifuging the cell supernatant for 3 min at 330 g to remove cell debris. Virus stocks were stored at −80°C. Vero E6 cells were cultured in DMEM supplemented with 2.5% (v/v) heat-inactivated FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x non-essential amino acid, 100 units/ml penicillin and 100 μg/ml streptomycin. 6,000 Vero E6 cells were seeded into 96-well plates the day before. Cells were incubated with 0--1000 μg/ml or 0--200 μg/ml PSVBS ([@B66]) in triplicates for 2 h at 37°C prior infection with ZIKV MR766. Two days later infection rates were determined with a cell-based ZIKV immunodetection assay. Cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature. Cell permeabilization was performed with cold methanol for 5 min at 4°C and cells were then washed with PBS. Afterward, cells were incubated with mouse anti-flavivirus antibodies 4G2 in antibody buffer for 1 h at 37°C, washed 3 times with washing buffer and incubated with a HRP-coupled anti-mouse antibody (1:20,000) for 1 h at 37°C. After 4 washing steps with PBS TMB substrate was added. After an incubation of 5 min at room temperature, reaction was stopped with 0.5 M sulfuric acid and absorption was measured at 450 nm and baseline corrected at 650 nm using an ELISA microplate reader. Values were corrected for the background signal derived from uninfected cells and triplicates were expressed as mean ± standard error derived from two independent experiments.

Effect of HBB(112--147) on HIV-1 Infection {#S2.SS7}
------------------------------------------

Virus stocks of CCR5-tropic HIV-1 NL4-3 92TH014.12 ([@B58]) were generated by transient transfection of HEK293T cells as described ([@B53]). Transfection mixture was replaced by 2 ml DMEM supplemented with 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin and 2.5% heat-inactivated FCS after overnight incubation. 40 h later, virus was collected by centrifuging the cell supernatant to remove cell debris for 3 min at 330 g. Virus stocks were stored at −80°C. For the infection assays, the reporter cell line TZM-bl was used and cultured in DMEM supplemented with 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin and 10% heat-inactivated FCS. 10,000 TZM-bl cells were seeded the day before into 96-well plates. The cells were incubated with 0--1000 μg/ml of HBB(112--147) or 0--50 μg/ml of heparin as control for 2 h at 37°C in triplicates prior infection with HIV-1. The TZM-bl cell line is stably transfected with an LTR-lacZ cassette and upon infection with HIV-1 the viral protein Tat is expressed, which activates the LTR and results in the β-galactosidase expression. Infection rates were determined 3 days later by detecting the β-galactosidase activity in cellular lysates using the Gal-Screen β-Galactosidase Reporter Gene Assay System for Mammalian Cells (Thermo Fisher Scientific) and the Orion II microplate luminometer (Berthold, Bad Wildbad, Germany). All values represent reporter gene activity (RLU/s) derived from triplicates minus background activities derived from uninfected cells. Triplicates are expressed as mean ± standard error derived from two independent experiments.

Effect of HBB(112--147) on Rubella Virus Infection {#S2.SS8}
--------------------------------------------------

40--60 plaque forming units each of the three rubella virus isolates Berlin.DE/17.97 (derived from a CRS case, genotype 1E), Bucuresti.ROU/25.03 (1G) and Rzeszow.POL/03.07 (1E) were incubated with 0--1000 μg/ml HBB(112--147) for 1 h. Mixtures were used to inoculate Vero cells. Cells were treated with CMC-Overlay and incubated at 37°C. Five days later, Rubella virus infection was quantified by an indirect immunocolorimetric assay using the monoclonal "Anti-Rubella-E1(MAB 925)" antibody as described elsewhere ([@B23]).

Colorimetric MTT- Based Cell Viability Assay {#S2.SS9}
--------------------------------------------

12,000 Vero E6 cells per well were seeded in 96-well flat bottom plates in 100 μl DMEM (supplemented with 2.5% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, and 1x non-essential amino acids) medium and incubated overnight. The next day, the medium was removed and 90 μl of X-vivo medium (supplemented with 2 mM L-glutamine and 100 units/ml penicillin, 100 μg/ml streptomycin) was added. HBB(112--147) was serially 1:2 diluted and 10 μl of each dilution was added to the cells. Cells were cultured in CO~2~ incubator at 37°C and cell viability was quantified after 48 h with the MTT-based assay. The medium was removed and 90 μl PBS and 10 μl MTT (5 mg/ml) solution were added per well. Following a 2.5 h incubation time at 37°C, supernatant was discarded and formazan crystals were dissolved in 100 μl 1:1 DMSO-EtOH solution. Absorption was measured at 450 nm and baseline was corrected at 650 nm using a Vmax kinetic microplate reader.

Protease Digestion Experiments {#S2.SS10}
------------------------------

Proteases used were Chymase (Sigma C8118), Cathepsin D (Sigma SRP6415), Cathepsin G (RP-77525), Cathepsin E (Biovision 7842), Pepsin (Roche 10108057001), Trypsin porcine pancreas (Sigma T0303-1G), Lysozyme from chicken egg white (Sigma L6876), Napsin A (RND 8489-NA). Digestion experiments were carried out with purified human hemoglobin (Sigma H7379) and recombinant or purified proteases. 100 μg hemoglobin (ca. 1.56 nmol) were digested with Chymase (in Tris-HCl 0.05 M, pH 8.0/0.26 M NaCl), Cathepsin D, G and E (in 0.2 M citrate buffer, pH 5.0), Pepsin (in 20 mM sodium acetate buffer, pH 3.5), Trypsin (in 0.1 M Tris--HCl, with 10 mM CaCl2, pH 8), Lysozyme (in 10 mM Tris-HCl, pH 8) or Napsin A (in 0.2 M NaCl, 0.1 M sodium acetate, pH 3.6). All proteases were used at a 1:100 molar ratio (15 pmol) and reactions were incubated at 37°C for 2 h.

SDS-PAGE {#S2.SS11}
--------

For SDS-PAGE, samples were incubated with Protein Loading Buffer (LiCor) and reducing agent and heated. Four microgram of hemoglobin was loaded per lane on a NuPAGE^TM^ 4--12% Bis-Tris Protein Gel (Thermo Fisher). After running, the gel was washed 1 × 5 min with ultrapure water, then fixed with 50% MeOH/7% acetic acid for 15 min and washed 3 × 5 min with ultrapure water. Staining was then performed with GelCode Blue (coll oidal coomassie) overnight. Destaining was done with ultrapure water until the background appeared clear, the gel then imaged in a LiCor Odyssey system.

Circular Dichroism (CD) {#S2.SS12}
-----------------------

CD spectra of pre-incubated peptide samples were measured on a JASCO J-1500 spectrometer in a 1 mm High Precision Cell by Hellma Analytics. An aqueous solution (MilliQ water) of HBB(112--147) was adjusted to pH 7 or pH 5 using 1 N HCl solution with a final concentration of 0.1 mg/ml. The samples with a volume of 300 μL were measured at room temperature. The CD signal was recorded from 260 to 180 nm with a bandwidth of 1 nm. The data pitch was set to 0.2 nm, while the scanning speed was 5 nm/min. Each sample was measured in three individual scans and the data were accumulated. Spectra are baseline corrected against MilliQ water, smoothened (Means Movement, convolution width 17) and normalized. The data was processed in the software Spectra Analysis and CD Multivariate SSE by JASCO.

Measurement of Napsin in Placenta Tissue by Dot Blot {#S2.SS13}
----------------------------------------------------

Using a methanol activated Immobilon-FL PVDF membrane (Merck, Part\# IPFL00010, LOT\# R6KA6693E) detection was carried out with anti-hNapsin A (R&D Systems Affinity Purified Rabbit IgG, Part\# AF8489, LOT\# CJEB0115011) and beta-Actin (8H10D10) Mouse antibody (Cell Signaling Technology, LOT\# 17) both 1:1000 diluted in blocking buffer over night after blocking with LiCor Odyssey Blocking Buffer (TBS) (Part\# 927-50000, LOT\# X2321). Detection was performed with IRDye 800 CW Goat anti-Rabbit 926-32211 (LOT\# C70426-05) and IRDye 680RD Goat anti-Mouse 926-68070 (LOT\# C70427-05) antibodies 1:10000 diluted for 1 h on a Li-Cor Odyssey CLx system with Image Studio (ver 5.2).

Identification of HBB(112--147) in the HB Digested Sample by LC-ESI-MSMS {#S2.SS14}
------------------------------------------------------------------------

Hemoglobin digests were reduced with 5 mM DTT for 20 min at RT and subsequently alkylated with iodoacetamide for 20 min at 37°C. The samples were measured using an LTQ Orbitrap Velos Pro system (Thermo Fisher Scientific) online coupled to an U3000 RSLCnano (Thermo Fisher Scientific) uPLC as described previously ([@B50]), with the following modifications: For separation, a binary gradient consisting of solvent A (0.1% FA) and solvent B (86% ACN, 0.1% FA) was employed. After loading onto the precolumn, the sample was concentrated and washed in 5% B for 5 min. In a first elution step, the percentage of B was raised from 5 to 15% in 5 min, followed by an increase from 15 to 40% B in 30 min. The column was washed with 95% B for 4 min and re-equilibrated for subsequent analysis with 5% B for 19 min. For visualization, spectral data was exported from the datafile using XCalibur Qual Browser 2.2 (Thermo Fisher Scientific, Bremen, Germany). Database searches were performed using PEAKs X^[1](#footnote1){ref-type="fn"}^ ([@B77]). For peptide identification, MS/MS spectra were correlated with the UniProt human reference proteome set^[2](#footnote2){ref-type="fn"}^. Carbamidomethylated cysteine was considered as a fixed modification along with oxidation (M) as a variable modification. False discovery rates were set on the peptide level to 1%.

Bacterial Strains {#S2.SS15}
-----------------

  -------------------------------------------------------------
  Strain                    Origin
  ------------------------- -----------------------------------
  *P. aeruginosa* BSU856    ATCC27853

  *P. aeruginosa* BSU1294   Clinical isolate, Ulm collection

  *P. aeruginosa* BSU1295   Clinical isolate, Ulm collection

  *P. aeruginosa* BSU1455   Clinical isolate, Ulm collection

  *P. aeruginosa* BSU1456   Clinical isolate, Ulm collection

  *P. aeruginosa* BSU1457   Clinical isolate, Ulm collection

  *P. aeruginosa* BSU1458   Clinical isolate, Ulm collection\
                            Carbapenem resistant ([@B26])
  -------------------------------------------------------------

Radial Diffusion Assay {#S2.SS16}
----------------------

Bacteria were cultured at 37°C in a 5% CO~2~ atmosphere overnight, pelleted by centrifugation and washed in 10 mM sodium phosphate buffer. Following resuspension in 10 mM sodium phosphate buffer optical density was determined at 600 nm (OD~600\ *nm*~). 2 × 10^7^ bacteria were seeded into a petri dish in 1% agarose dissolved in 10 mM sodium phosphate buffer. After cooling at 4°C for 30 min 2--3 mm holes were punched into the 1% agarose. Peptides adjusted to the desired concentration in 10 μl of ddH~2~O were filled into the agar-holes. Following incubation at 37°C in ambient air for 3 h plates were overlaid with 1% agarose solution containing 3% tryptic soy broth (TSB) dissolved in 10 mM phosphate buffer. Inhibition zones in cm were determined following 16--18 h incubation time at 37°C in a 5% CO~2~ atmosphere and used to evaluate antibacterial potency. For LPS inhibition experiments, 62.5 μg/ml HBB(112--147) was incubated for 1 h at 37°C together with varying concentrations of LPS of *P. aeruginosa* 10 (Sigma L9143) followed by the same procedure as described above.

Survival Assay {#S2.SS17}
--------------

*P. aeruginosa* BSU856 cells were grown in THY broth \[Todd-Hewitt Broth (Oxoid) supplemented with 0.5% yeast extract (BD, Miami, United States)\] at 37°C in a 5% CO~2~ atmosphere overnight. 1 ml of the culture adjusted to an OD~600*nm*~ of 0.1 was centrifuged and the bacterial pellet was resuspended in 1 ml of assay medium (5% TSB dissolved in 0.9% NaCl adjusted to different pH values). 90 μl microliter of the bacterial suspension was mixed with 10 μl of HBB(112--147) of the desired concentration or with 10 μl of ddH~2~O (negative control) followed by incubation at 37°C. Samples were taken at the indicated time points, dilutions were prepared and platted on sheep blood agar plates (TSA + SB, Oxoid, Basingstoke, United Kingdom). Colony Forming Units (CFU) were counted after overnight incubation of the agar plates at 37°C in a 5% atmosphere and the survival of the cells was calculated in comparison to the CFU present at the beginning of the experiment (*t* = 0 min) and normalized to the mock treated bacterial sample grown in the corresponding assay medium.

SYTOX Green Membrane Permeabilization Assay {#S2.SS18}
-------------------------------------------

An equivalent of 100 μl of an OD~600\ *nm*~ of 0.1 of mid-exponential *P. aeruginosa* BSU856 cells were harvested by centrifugation and resuspended in 5% TSB dissolved in 0.9% NaCl adjusted to three different pH values (pH 7, pH 5.5, pH 4.5). The samples were treated with HBB(112--147) of different concentrations or were mock treated with ddH~2~O. After incubation at 37°C for 1 h, the cells were pelleted and resuspended in 5% TSB dissolved in 0.9% NaCl adjusted to pH 7 containing 0.2 μM SYTOX green stain. The fluorescent intensity of the samples was measured in a Tecan infinite M200 plate reader with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. The relative fluorescence of the samples was calculated by normalizing the peptide treated samples to the mock treated samples grown in the corresponding assay medium.

Transmission Electron Microscopy {#S2.SS19}
--------------------------------

*P. aeruginosa* BSU856 cells, grown till mid-exponential growth phase, were harvested by centrifugation and resuspended in 5% TSB dissolved in 0.9% NaCl (pH 4.5). 5 × 10 ([@B51]) cells were treated with 0.1 mM HBB(112--147) for 1 h at 37°C followed by centrifugation. The pelleted cells were fixed with 2.5% glutaraldehyde containing 1% saccharose in phosphate buffer (pH 7.3). Samples were washed five times with phosphate buffer and post-fixed in 2% aqueous osmium tetroxide. After dehydrating the samples in a graded series of 1-propanol, they were blockstained in 1% uranyl acetate and embedded in Epon. Ultra-thin sections (80 nm) were collected on copper grids, contrasted with 0.3% lead citrate for 1 min and imaged in a Zeiss TEM 109 or in a Jeol TEM 1400.

Evolutionary Conversation of HBB(112--147) Sequence in Hemoglobin {#S2.SS20}
-----------------------------------------------------------------

The following orthologs of the hemoglobin beta globin chain were included in the sequence analysis (numbers give accession numbers): Homo sapiens (Human) [P68871](P68871); Rattus norvegicus (Rat) [P02091](P02091); Mus musculus (Mouse) [P02088](P02088); Sus scrofa (Pig) [P02067](P02067); Oryctolagus cuniculus (Rabbit) [P02057](P02057); Pan troglodytes (Chimpanzee) [P68873](P68873); Bos taurus (Bovine) [P02070](P02070); Mesocricetus auratus (Golden hamster) [P02094](P02094); Ovis aries (Sheep) [P02075](P02075); Macaca fascicularis (Cynomolgus monkey) [P68223](P68223); Panthera pardus orientalis (Amur leopard) [P04244](P04244); Capra hircus (Goat) [P02077](P02077); Bradypus tridactylus (Pale-throated three-toed sloth) [P14526](P14526); Ailuropoda melanoleuca (Giant panda) [P18983](P18983); Dasypus novemcinctus (Nine-banded armadillo) [P02087](P02087); Macropus eugenii (Tammar wallaby) [Q6H1U7](Q6H1U7); Tachyglossus aculeatus aculeatus (Australian echidna) [P02110](P02110); Xenopus laevis (African clawed frog) [P02132](P02132); Chelonoidis carbonarius (Red-footed tortoise) [Q98905](Q98905); Meleagris gallopavo (Common turkey) [P81023](P81023); Gallus gallus (Chicken) [P02112](P02112); Danio rerio (Zebrafish) [Q90486](Q90486);

Protein sequences were aligned using Clustal W^[3](#footnote3){ref-type="fn"}^ and residue conservation was determined using the Scorecons Server^[4](#footnote4){ref-type="fn"}^. Shannon's information theoretical entropy was applied to measure the diversity of amino acids at a specific site. Residues were classified into one of seven types: aliphatic (AVLIMC), aromatic (FWYH), polar (STNQ), positive (KR), negative (DE), special conformations (GP) and gaps. This convention follows that of [@B49]. Statistical calculations were performed with a two-tailed unpaired Student's *t*-test using Graph Pad Prism Version 5.0.

Results {#S3}
=======

Identification of Placenta-Derived Peptide Fractions That Simultaneously Reduce HSV-2 Infection and Growth of *P. aeruginosa* {#S3.SS1}
-----------------------------------------------------------------------------------------------------------------------------

In an attempt to identify endogenous antiviral and antibacterial peptides in placenta, we generated a peptide library from 10 kg of pooled homogenized placental tissue. Human tissue was obtained from healthy individuals in a maternity ward of a local hospital and was processed immediately after delivery. Peptides were extracted by an ice-cold acetic acid extraction procedure and the obtained peptide and protein fractions were separated by ultrafiltration (cut-off: 50 kDa). The peptide fraction was then chromatographically separated and resulted in approx. 250 different peptide containing fractions that were used for bioscreening ([@B41]). To identify peptides with anti-HSV-2 activity, all fractions of pH pools 0--4 were dissolved in PBS and added to ELVIS^TM^ cells, an HSV-2 reporter cell line expressing β-galactosidase upon viral infection. Thereafter, cells were infected with HSV-2 and infection rates determined 2 days later (before occurrence of viral CPE) by quantifying β-galactosidase activity in cellular lysates. Only fraction 8 of pH pool 2 and fractions 18--20 of pH pool 4 markedly suppressed HSV-2 infection ([Supplementary Figure S1A](#DS1){ref-type="supplementary-material"}). To confirm these results, a twice as high concentration of these fractions was tested again for anti-HSV-2 activity. Antiviral activity of fraction 8 of pH pool 2 could not be confirmed (not shown), however, fractions 18 and 19 inhibited HSV-2 infection by ∼80% ([Figure 1A](#F1){ref-type="fig"}). Interestingly, the same fractions of pH pool 4 were also the most potent inhibitors of growth of *P. aeruginosa* ([Supplementary Figure S1B](#DS1){ref-type="supplementary-material"}).

Subsequent mass spectrometric analysis by MALDI-MS revealed a predominant peptide with a mass of 3902.5 Da ([Figure 1B](#F1){ref-type="fig"}). Edman sequencing allowed to determine the N-terminal sequence starting with VCVLA... and database search identified the corresponding peptide: a 36-mer derived from the C-terminal region of the hemoglobin subunit β (HBB) encompassing residues 112--147 ([Figure 1B](#F1){ref-type="fig"}, numbering according to UniProt sequence P68871). The same peptide was previously isolated by us from a similar placenta library and shown to exert antibacterial activity against Gram-positive and -negative bacterial species ([@B41]). However, no antiviral activity was reported. Thus, we next determined the anti-HSV-2 activity of placenta-purified HBB(112--147) and that of the chemically synthesized version. As shown in [Figure 1C](#F1){ref-type="fig"}, both peptides resulted in a dose-dependent inhibition of HSV-2 infection with IC~50~ values in the median μg/ml range, without causing cytotoxic effects ([Supplementary Figure S2](#DS1){ref-type="supplementary-material"}). Thus, placenta contains a C-terminal hemoglobin β fragment that restricts growths of bacteria and inhibits HSV-2 infection. As resistance to conventional anti-HSV drugs such acyclovir (ACV) is a growing problem especially with HSV-2 in immunocompromised patients ([@B60]), we investigated whether HBB(112--147) is also effective against ACV-resistant HSV-2. Indeed, a highly ACV-resistant clinical HSV-2 isolate was equally inhibited by the peptide as the HSV-2 333 lab strain ([Figure 1D](#F1){ref-type="fig"}).

HBB(112--147) Inhibits HSV-2 Infection by Blocking Viral Entry {#S3.SS2}
--------------------------------------------------------------

We next analyzed the antiviral mechanism of HBB(112--147). For this, cells were exposed to increasing concentrations of the peptide for 30 min. Thereafter, cells were either infected directly with HSV-2 (cell treatment), or washed and subsequently infected (wash). Additionally, virions were first treated with the peptide for 3 h at indicated concentrations, and then used to infect cells, resulting in 20-fold reduced concentrations of HBB(112--147) in cell culture (virion treatment). No inhibitory activity was observed if peptide was removed by washing prior to infection, suggesting that the hemoglobin fragment needs to be present during infection and that it does not induce an antiviral state of cell ([Figure 2](#F2){ref-type="fig"}). If added 30 min prior to infection, HBB(112--147) dose-dependently reduced infection with an IC~50~ of ∼200 μg/ml, confirming results shown above ([Figure 2](#F2){ref-type="fig"}) and demonstrating that it blocks an early step in the viral life cycle. Interestingly, exposure of the virions prior to infection also suppressed infection (virion treatment). The two highest concentrations tested, 500 and 1000 μg/ml, reduced HSV-2 infection by 60 and 78%, respectively. These concentrations correspond to final cell culture concentrations of 25 and 50 μg/ml, that hardly reduce infection, suggesting that HBB(112--147) seems to interact with the HSV-2 particles in a way that prevents infection. Consistent with an entry-inhibiting effect, HBB(112--147) only exerted potent inhibition if added to cells prior to infection (directly or with 30 min pre-incubation), but did not inhibit HSV-2 infection if added 2 or 16 h after infection ([Figure 2B](#F2){ref-type="fig"}). This is consistent with inhibition by Heparin, a well-described HSV entry inhibitor preventing virion adsorption ([Supplementary Figure S3](#DS1){ref-type="supplementary-material"}).

HBB(112--147) Does Not Affect HSV-1, HIV-1, Zika and Rubella Virus Infection {#S3.SS3}
----------------------------------------------------------------------------

We next tested whether the hemoglobin fragment may also inhibit HSV-1 infection. Surprisingly, HBB(112--147) did not block infection of a clinical HSV-1 isolate whereas it was active against a second HSV-2 isolate tested ([Figure 3A](#F3){ref-type="fig"}). We next determined the effect of the peptide on viruses for which dia-placental transmissions have been reported. HBB(112--147) and the polyanion heparin as control ([@B68]) were titrated on TZM-bl cells, an HIV-1 reporter cell line that expresses β-galactosidase upon infection. As shown in [Figure 3B](#F3){ref-type="fig"}, the polyanion inhibited HIV-1 infection in a dose-dependent manner whereas HBB(112--147) was inactive. Likewise, no inhibition of Zika Virus (ZIKV) infection of Vero cells was observed, as shown by immunodetection assay using a flavivirus antibody-based ELISA ([@B52]), whereas the macromolecular polyanion PSVBS ([@B66]) was active ([Figure 3C](#F3){ref-type="fig"}). For both ZIKV and HIV-1, even virus treatment with up to 1 mg/ml HBB(112--147) on virus did not result in any inhibition, while the molecular tweezer CLR01 resulted in destruction of both virions as previously published ([Supplementary Figure S4](#DS1){ref-type="supplementary-material"}). Similarly, no antiviral effect of HBB(112--147) against three different Rubella virus (RUBV) isolates, one isolated from a patient with congenital rubella syndrome, were observed, as shown by indirect immunocolorimetric detection of RUBV infection in Vero cells ([Figure 3D](#F3){ref-type="fig"}). Thus, HBB(112--147) is no broad-spectrum antiviral agent but rather a specific inhibitor of HSV-2.

![Antiviral activity of HBB(112--147) against HSV-1, HIV-1, ZIKV and RUBV. **(A)** Peptide was added to ELVIS cells and cells then infected with one clinical HSV-1 isolates and a second isolate of HSV-2. Infection rates were determined two days later by quantifying β-galactosidase activities. **(B)** TZM-bl reporter cells were incubated with HBB(112--147) or the polyanion Heparin and then infected with HIV-1. Three days post-infection, infection was determined by measuring β-galactosidase activities in cellular lysates. **(C)** Vero E6 cells were supplement with HBB(112--147) or the macromolecular compound PSVBS and infected with ZIKV-MR766. Two days later, infection was quantified by an in cell ELISA that detected the viral E protein. Values shown in **(A--C)** are mean values derived from triplicate experiments. **(D)** Three rubella virus isolates were exposed to indicated concentrations of HBB(112--147) and then inoculated onto Vero cells. Cells were treated with CMC-Overlay and incubated at 37°C. Five days later, RUBV infection was quantified by an indirect immunocolorimetric assay using the monoclonal anti-Rubella-E1(MAB 925) and photos taken by a digital camera.](fmicb-11-00508-g003){#F3}

Proteolytic Generation of HBB(112--147) {#S3.SS4}
---------------------------------------

In adults, the most common hemoglobin type is a tetramer called hemoglobin A, consisting of two α and two β subunits that are non-covalently bound (α2β2). In this tetrameric state, the putative protease cleavage site in the β subunits at positions L111 and V112 is not solvent exposed and hence not accessible for proteases ([Supplementary Figure S5](#DS1){ref-type="supplementary-material"}). However, α2β2 rapidly dissociates into respective dimers and monomers at acidic pH ([@B29]). Thus, we analyzed whether HBB(112--147) can be generated under low pH conditions by acidic proteases. In order to determine which proteases might be responsible for the proteolytic liberation of HBB(112--147) from full-length hemoglobin, purified human hemoglobin was subjected to digestion by a panel of 8 proteases. Digestion with Chymase, Cathepsin D as well as Pepsin, Trypsin and Napsin A ([Figure 4](#F4){ref-type="fig"}) resulted in lower signal for uncleaved monomeric globin (16 kDa) and generation of smaller fragments. As bands consistent with a size of HBB(112--147) at approximately 4 kDa were especially observed for digestions with Cathepsin D, Pepsin and Napsin A, those digestions were also subjected to mass spectrometric analysis in order to confirm generation of HBB(112--147). Indeed, Cathepsin D and Napsin A-digested hemoglobin yielded a signal consistent with generation of HBB(112--147) ([Supplementary Figure S6](#DS1){ref-type="supplementary-material"}). No such signal was detected in Pepsin-digested hemoglobin (not shown), suggesting generation of another peptide fragment with similar size. In kinetic digestion experiments with Cathepsin D, a fragment running at the same height as synthetic HBB(122--147, 3902.5 kD) was observed already at the first time point (20 min), while no fragments were generated in a buffer-only mock digestion ([Supplementary Figure S7](#DS1){ref-type="supplementary-material"}). As Napsin A has not been previously described to be expressed in placental tissue, we analyzed a placenta homogenate by dot blot analyses using a Napsin A specific antibody. As shown in [Supplementary Figure S6](#DS1){ref-type="supplementary-material"}, Napsin A is readily detectable in the placenta homogenate ([Supplementary Figure S8](#DS1){ref-type="supplementary-material"}).

![Generation of HBB(112--147) by proteolytic digestion. Purified human hemoglobin was incubated with several proteases (at 1:100 molar ratio) and digested for 2 h at 37°C or incubated with the respective buffer only for the same time (bottom). The reactions were then separated by SDS-PAGE and total protein stained by colloidal coomassie. For the bottom panel, human hemoglobin was incubated in the respective digestion buffers without addition of protease and separated as well.](fmicb-11-00508-g004){#F4}

Conservation Score and Biophysical Characterization of HBB(112--147) {#S3.SS5}
--------------------------------------------------------------------

To determine the evolutionary conservation of the HBB(112--147) peptide sequence, we aligned the β-hemoglobin orthologs of 22 vertebrate species ([Supplementary Figure S9](#DS1){ref-type="supplementary-material"}, bottom right) and determined the conservation score, i.e., the diversity of amino acids at each site ([Supplementary Figure S9](#DS1){ref-type="supplementary-material"}, top). The average conservation score of residues within HBB(112--147) was not significantly different from that outside this region ([Supplementary Figure S9](#DS1){ref-type="supplementary-material"}, bottom left). This suggests that the HBB(112--147) sequence is evolutionarily not more conserved than the remainder of the β-hemoglobin protein. Analysis of the HBB(112--147) sequence by ProtParam tool revealed a positive isoelectric point (pI) of 9.05, a net excess of two positively charged residues, and an estimated half-life of \>100 h in mammalian reticulocytes, characterizing the peptide as very stable. We determined the CD spectra of HBB(112--147) at neutral and acidic pH. As shown in [Figure 5](#F5){ref-type="fig"}, the peptide adopts mainly a random coil structure with modest contribution of other structures while the content of secondary structures is not changed significantly if the peptide is dissolved in solutions with acidic or neutral pH. This lack of ordered structures and high random coil content could be an indication of intrinsically disordered structures ([@B11]; [@B75]). Several antimicrobial peptides (AMPs) are known to form disordered regions that could adopt more ordered states upon binding to their cellular targets ([@B19]; [@B72]; [@B11]; [@B75]). However, the functional role of these intrinsically disordered proteins has been recognized only recently ([@B19]), and further analysis and structure mining would be necessary to clarify whether the high random coil content of HBB(112--147) could change upon interaction with its target.

![CD spectra of HBB(112--147). **(A)** The peptide was dissolved in MilliQ water at pH 5 and 7 and CD spectra were recorded. **(B)** Secondary structure elements of HBB(112--147) based on the analysis of CD spectra results; spectra were baseline corrected against MilliQ water, smoothened and normalized. Values shown were derived from triplicate measurements (+SD).](fmicb-11-00508-g005){#F5}

HBB(112--147) Inhibits Growth of Several Clinical Isolates of *Pseudomonas aeruginosa* {#S3.SS6}
--------------------------------------------------------------------------------------

*P. aeruginosa* is a frequent nosocomial pathogen causing many life-threatening infections that are often complicated through the worldwide occurrence of multi-resistant strains. To assess if placental tissue may represent a source for AMPs exhibiting anti-pseudomonal activity we screened a peptide library against *P. aeruginosa* strain ATCC27853. One of the fractions with the highest activity against *P. aeruginosa* (fraction 19) contained large amounts of HBB(112--147) ([Supplementary Figure S1B](#DS1){ref-type="supplementary-material"}). To substantiate these results and to confirm that the antimicrobial compound in this fraction was HBB(112--147), various clinical *P. aeruginosa* isolates and strain ATCC27853 were evaluated for susceptibility against this purified hemoglobin fragment in radial diffusion assays. All of the strains investigated demonstrated a susceptibility to HBB(112--147) in a dose dependent manner down to concentrations as low as than 15.6 μg/ml ([Figure 6](#F6){ref-type="fig"}). To explore if HBB(112--147) is also effective against a multiresistant strain of this species, we determined HBB(112--147) susceptibility of a carbapenem resistant *P. aeruginosa* strain, that had previously shown antibiotic susceptibility only to Colistin, a toxic, last resort antibacterial compound ([@B26]). Inhibition zones for this strain were indistinguishable from values obtained for other clinical *P. aeruginosa* isolates ([Figure 6](#F6){ref-type="fig"}, red column).

![Antibacterial activity of HBB(112--147) against clinical *Pseudomonas aeruginosa* isolates. The effect of indicated concentrations of HBB(112--147) was tested against several clinical isolates of *Pseudomonas aeruginosa* in a radial diffusion assay. BSU1458 (red) is a carbapenem/multi-drug resistant *P. aeruginosa* isolate. Depicted are inhibition zones in cm observed in a radial diffusion assay (*n* = 3, mean values +SD).](fmicb-11-00508-g006){#F6}

The Antibacterial Effect of HBB(112--147) Is pH Dependent {#S3.SS7}
---------------------------------------------------------

Many antimicrobial peptides show highest antibacterial activity at a pH below 7 ([@B47]) and isolation of HBB(112--147) from placental tissue was carried out under acidic conditions. Furthermore slightly acidic conditions are present in the radial diffusion assay that we used for screening of the placental library as well as for the evaluation of the susceptibility of *P. aeruginosa* against HBB(112--147). To investigate a potential pH dependency of the antimicrobial effect of HBB(112--147), bacterial survival assays were carried out under different pH conditions. An overnight culture of *P. aeruginosa* was resuspended to an OD of 0.1 and adjusted to pH values of 4.5, 5.5, and 7. Following exposure to 5--50 μM concentrations of HBB(112--147) bacterial survival was quantified through CFU measurements. After 15 min at pH 4.5 less than 10% of the *P. aeruginosa* cells growing in control tubes of the same pH without HBB(112--147) were still viable, a value which dropped to less than 1% after 60 min ([Figure 7A](#F7){ref-type="fig"}). At pH 7 little if any growth inhibition could be observed when compared to the appropriate controls even after 60 min at 50 μM concentration of HBB(112--147) ([Figure 7A](#F7){ref-type="fig"}).

![Effect of HBB(112--147) on bacterial survival and membrane integrity. **(A)** The effect of HBB(112--147) on *P. aeruginosa* growth was quantified in a survival assay. 5, 10, and 50 μM of the peptide were added to an overnight culture of *P. aeruginosa* at pH values of 7, 5.5, and 4.5 for 15, 30, and 60 min. Bacteria were quantified by CFU determination. Values are expressed as % of growth controls not exposed to HBB(112--147). Data shown are average values derived from three biological replicates +SD. **(B)** Plasma membrane damage of *P. aeruginosa* following HBB(112--147) treatment for 1 h at 37°C, was tested at indicated pH values by uptake of SYTOX green and subsequent quantification of fluorescence in a Tecan infinite M200 plate reader. Shown are mean values and SD of *n* = 3. Values shown are relative fluorescence units (RFU).](fmicb-11-00508-g007){#F7}

HBB(112--147) Destroys the Membrane Integrity of *P. aeruginosa* {#S3.SS8}
----------------------------------------------------------------

Bacterial membrane damage is one of the most common modes of action for AMPs. To elucidate if this is also the relevant antimicrobial mechanisms for HBB(112--147) against *P. aeruginosa*, we investigated bacterial membrane integrity via SYTOX green uptake into bacterial cells. Intracellular SYTOX green enrichment and staining of nucleic acids occurs only upon disruption of bacterial membranes. Following exposure of HBB(112--147) for 1 h at 37°C, membrane integrity was compromised already at 5 μM concentrations for pH 4.5 and showed a clear dose dependent effect ([Figure 7B](#F7){ref-type="fig"}). In support of the results obtained for the antibacterial effect, also membrane permeabilization was pH dependent. At pH 7 even at a 50 μM concentration of HBB(112--147) hardly any SYTOX enrichment could be detected in *P. aeruginosa*. To visualize loss of membrane integrity transmission electron microscopy (TEM) was performed. Treatment of *P. aeruginosa* cells was carried out with 0.1 mM HBB(112--147) for 1 h at pH 4.5. Subsequent TEM pictures revealed the presence of multiple lysed bacterial cells and leakage of intracellular content ([Figures 8C,D](#F8){ref-type="fig"}), while controls appeared intact ([Figures 8A,B](#F8){ref-type="fig"}). Areas of disrupted bacterial membranes are clearly visible in TEM ([Figure 8E](#F8){ref-type="fig"}) of bacterial cells exposed to HBB(112--147). To further investigate bacterial surface molecules of *P. aeruginosa*, that might interact directly with HBB(112--147), we performed a preincubation of HBB(112--147) with *P. aeruginosa* LPS for 1 h. Subsequent testing of antimicrobial activity in radial diffusion assays, showed a dose dependent reduction of the inhibitory effect ([Supplementary Figure S10](#DS1){ref-type="supplementary-material"}), indicating that HBB(112--147) binds to LPS.

![Transmission electron microscopy images of *P. aeruginosa*. Bacterial cells were grown to midlogarithmic phase and exposed to buffer **(A,B)** or 0.1 mM HBB(112--147) at pH 4.5 for 1 h **(C,D)**. Cells were fixed with 2.5% glutaraldehyde and dehydrated in a graded series of 1-propanol. Following embedding in Epon, ultra-thin sections (80 nm) were collected on copper grids, and imaged in a Zeiss TEM 109 or in a Jeol TEM 1400. Areas showing loss of membrane integrity are indicted by black arrows **(E)**. Scale bars are 5 μm **(A,C)** and 1 μm **(B,D)**.](fmicb-11-00508-g008){#F8}

Discussion {#S4}
==========

In the present study, we screened a placental peptide library for antiviral agents and identified a C-terminal fragment of β-hemoglobin as specific inhibitor of HSV-2 infection. This peptide, termed HBB(112--147) has previously been isolated from the same source as broad-spectrum antibacterial agent ([@B41]). Here, we confirm and expand these findings and demonstrate that HBB(112--147) is also active against clinical isolates of *P. aeruginosa*, including a multiple-drug resistant strain ([@B26]). Our novel data also show that the peptide ruptures the bacteria cell wall in a pH-dependent manner resulting in release of the cytosol and consequently cell death. Moreover, we show that HBB(112--147) is generated from tetrameric hemoglobin by ubiquitously expressed aspartic proteases under acidic conditions, which are a hallmark of inflammatory tissues.

HBB(112--147) is the predominant peptide in those fractions of the peptide library (fr. 18 and 19 of pH pool 4) that inhibited HSV-2 and *P. aeruginosa*. Peptide purified from placenta and the synthetic version showed comparable antiviral activity, strongly suggesting that only the HBB(112--147) fragment but no other peptide or protein are responsible for the observed antiviral activity in these fractions. Unlike its broad antibacterial activity against various Gram-positive and -negative bacteria ([@B41]), HBB(112--147) selectively inhibits HSV-2 but no other viral pathogen, suggesting a different antibacterial and antiviral mechanism. In fact, we show that HBB(112--147) has direct bacterial cell killing activity by inducing ruptures in the bacterial cell wall. We also demonstrate that HBB(112--147) interacts with HSV-2 particles in a way that prevents viral entry, whereas no inhibition of other enveloped viruses (HIV-1, ZIKV, RUBV, and HSV-1) was observed. Virion pre-treatment of HSV-2 did not yield overall higher inhibition rates, indicating that the effect is not due to virion disruption. As IC~50~ were nonetheless substantially lower in virion- compared to cell-treatment mode, we propose HBB(112--147) to interfere with the interaction of viral glycoproteins with a cellular receptor. It cannot be excluded that non-protein structures of the viral envelope (lipids, carbohydrates) might also be targets of HBB(112--147). However, infection-inhibitory membrane interactions would likely result in membrane disruption (as e.g., for CLR01 used in [Supplementary Figure S4](#DS1){ref-type="supplementary-material"}) and are not consistent with the overall higher inhibition observed upon cell treatment ([Figure 2](#F2){ref-type="fig"}).

HSV-1 and HSV-2 are closely related viruses with a high sequence homology of 83% in the protein-coding regions ([@B16]), which mediate cellular attachment and entry. The differential activity of HBB(112--147) against HSV-1 and HSV-2 may reflect differences in the glycoprotein sequence and/or composition of both viruses. In fact, both viruses differ in their sensitivity to polyanions ([@B30]) and polycations ([@B39], [@B40]), differential binding to heparan sulfate (HS)/heparin chains ([@B27]; [@B73]) and stimulation of viral infection in glycosaminoglycan-deficient cells by dextran sulfate ([@B18]). Collectively these data suggest that HBB(112--147) may interact with an HSV-2 specific glycoprotein that is important for viral attachment and/or entry. The fact that antibacterial and antiviral action is exerted via a different mechanism is likely due to conformational changes of HBB(112--147) upon encounter of LPS on the surface of *P. aeruginosa* as it has been described for several other AMPs ([@B62]). The subsequent rearrangements and membrane disruption may thus only occur at bacterial membranes and not the surface of virions. Whether interaction with viral surfaces leads to other conformation changes or the peptide is active as a random coil in this scenario remains to be studied.

As a common sexually transmitted infection, HSV-2 has a relatively high seroprevalence of 10--30% in the US and Europe and up to 30--80% in the female population of some developing countries ([@B48]; [@B74]; [@B44]). As oral HSV-1 infection is typically already acquired during childhood or adolescence, it is much more prevalent at ca. 60--90% seropositivity in developed countries ([@B70]). While infection with either virus is often either asymptomatic or results in characteristic skin lesions, severe outcomes such as herpes simplex encephalitis (HSE) in neonates or aseptic meningitis in adults are also observed ([@B7]). Neonatal HSE is a particularly severe disease caused by HSV-2 infection in 70% of cases, leading to CNS involvement in 70% of cases and death in 60% of cases if untreated ([@B12]). Interestingly, vertical transmission of HSV-2 from mother to child happens perinatally in the majority of cases, while only 5% of transmission occur *in utero* ([@B34]). Despite relatively high shedding rates (compared to HSV-1) in infected women ([@B67]), vertical HSV transmission is generally a rare event, occurring in up to 1/3,000 live births ([@B9]) and HSV-2 is responsible for the majority of those infections ([@B3]). Multiple factors affect these low transmission rates: the lack of HSV receptor expression on syncytiotrophoblasts ([@B35]), transplacental transmission of protective antibodies ([@B9]) as well as low viremia in most HSV-2 patients in absence of primary infection. Despite these factors, one clinical study found HSV-2 DNA in 9% of maternal-side placenta tissue with 39% of these cases also testing positive for HSV-2 DNA on the fetal side; notably despite lack of symptoms in any of the patients at delivery ([@B22]). Congenital infection with other herpesviruses is substantially more common: CMV infection occurs in 0.2--2.2/100 live births, while congenital VZV infection is reported with an incidence of up to 0.4--9/100 births. Notably, these numbers account for congenital infections, meaning *in utero* transmission of the virus, which is a minor occurrence for HSV-2. Considering the potent inhibition of HSV-2 infection by HBB(112--147) and the abundance of the precursor in placental tissue, a role of the peptide in preventing vertical transmission of HSV-2 *in utero* seems plausible and further experiments are needed to confirm its role *in vivo*.

*P. aeruginosa* is listed among the six bacterial species summarized as ESKAPE pathogens that pose an increased health risk to patients due to their common multidrug resistance profiles ([@B59]). It is responsible for a wide variety of nosocomial infections and the major bacterial agent in chronic lung infections of cystic fibrosis patients ([@B46]). In cystic fibrosis as well as in other serious *P. aeruginosa* caused infections the steady increase of multi-resistant *P. aeruginosa* strains severely limits therapeutic options. Often highly toxic substances such as Colistin represent the only therapeutic options for multidrug resistant strains ([@B26]). To address this alarming clinical problem, we used the same peptide library originating from human placenta to identify antimicrobial substances targeting *P. aeruginosa*. Interestingly the fractions exhibiting the highest antimicrobial activity against *P. aeruginosa* were also the most active fractions against HSV-2. While screening was carried out with an ATCC laboratory strain, subsequent determination of antimicrobial activity was done on *P. aeruginosa* clinical isolates including a multidrug resistant carbapenemase expressing strain ([@B26]). Susceptibility to HBB(112--147) showed a dose dependent effect and proved to be very similar in all of the clinical isolates we tested. Interestingly, many AMPs display antimicrobial activity preferably at low pH conditions. The survival rates of *P. aeruginosa* in the presence of HBB(112--147) were greatly affected by pH and showed the highest activity of HBB(112--147) at a pH of 4.5. Acidic pH values are found in various host niches such as the vaginal tract, the skin, the stomach, intracellularly in lysosomal compartments and at sites of bacterial infections. Many of the well-known human AMPs such as lactoferrin, LL37, dermicidin, kappacins and histatins show pH dependent antimicrobial activities ([@B47]).

Indeed, biophysical analysis of HBB(112--147) revealed features characteristic for many AMPs. This class of innate host defense molecules are 12--50 amino acids, include two or more positively charged residues provided by arginine, lysine or, in acidic environments, histidine, and a large proportion (generally \> 50%) of hydrophobic residues ([@B69]; [@B57]; [@B17]). HBB(112--147) is a 36-mer with three positively charged residues (K10, K22, K34), and additionally four histidine residues, which may explain the increased antibacterial activity of HBB(112--147) under acidic conditions. Conformational changes of AMPs leading to an increase of alpha helical structures occur at low pH and represent a hallmark of pore forming AMPs. Under low pH conditions protonation of histidine residues occurs in some AMPs ([@B32]) and promotes conformational changes that improve their capacity for insertion into bacterial membranes and pore formation ([@B33]). Many AMPs are unstructured in free solution \[as HBB(112--147) is\], and fold into their final configuration upon partitioning into biological membranes resulting in the disruption of bacterial membrane integrity. Especially for pH dependent AMPs, bacterial pore formation is the preferred molecular mechanism ([@B47]). Based on our SYTOX experiments that detected pH-dependent membrane damage, bacterial lysis seems to occur in *P. aeruginosa* upon exposure to HBB(112--147). This interpretation is supported by the analysis of TEM pictures that shows defects of bacterial membranes as well as spilling of bacterial intracellular content and a large proportion of apparently lysed bacterial cells. To achieve bacterial lysis, HBB(112--147) needs to interact with bacterial surface structures. LPS has previously been implicated to interact with HBB(112--147) ([@B41]), however, if this interaction could be important in regard to the antimicrobial properties of HBB(112--147) has not been investigated. We could show here that the preincubation of HBB(112--147) with soluble *P. aeruginosa* LPS reduced its antibacterial activity in a dose dependent manner, most likely through competitive inhibition. The cationic and hydrophobic nature of many AMPs facilitates the interaction with negatively charged bacterial molecules such as LPS. Several antimicrobial peptides are known to interact with LPS, targeting AMPs to the bacterial cell surface as well as exerting an anti-inflammatory effects by blocking host reactions like cytokine release ([@B62]). Based on the data we obtained, HBB(112--147) appears to have a similar mode of action and can be classified as typically cationic AMP.

The prerequisites for the generation of HBB(112--147) -- the hemoglobin precursor and the peptide releasing protease Cathepsin D -- are given almost everywhere in the body. We show that HBB(112--147) is released under acidic conditions by Cathepsin D, an aspartic endo-protease that is ubiquitously distributed in lysosomes of all cells ([@B4]). The main function of Cathepsin D is to degrade proteins and activate precursors of bioactive proteins in pre-lysosomal compartments ([@B15]). However, Cathepsin D can also be found in the extracellular space ([@B43]; [@B5]). The trigger for the proteolytic degradation of hemoglobin and the liberation of HBB(112--147) is an acidic pH which is a hallmark of inflammatory tissues and infections ([@B21]). A low pH not only activates the protease but also results in the dissociation of the hemoglobin subunits and the exposure of the otherwise buried proteolytic cleavage site ([@B29]). The second protease we found to release HBB(112--147) is Napsin A, a less explored aspartic protease present in the lung and kidney. While there is no description of Napsin A being expressed in placental tissue in literature, we detected Napsin A in placenta homogenate using specific antibodies. Our findings suggest that a local acidification at sites of infection or inflammation result in the rapid generation of HBB(112--147) that acts as broad-based antibacterial (and anti-HSV-2) agent.

The concentrations of HBB(112--147) that are required to suppress HSV-2 infection or bacterial growth are in the high μg/ml range. However, these seemingly high concentrations can be readily achieved *in vivo* because the hemoglobin precursor and the AMP-releasing protease are present almost everywhere in the human body. Hemoglobin is the second most abundant protein in humans with concentrations of 12--20 g in every 100 ml of human blood, and 50 g in spleen and bone marrow. 15 g of the tetrameric hemoglobin per 100 ml blood corresponds to 150 mg per 1 ml, and ∼75 mg of the β-hemoglobin subunits per ml blood. Complete proteolytic processing of hemoglobin (as it occurred in our *in vitro* digestions) would result in concentrations of ∼18 mg/ml of HBB(112--147). Even if only 10% of available hemoglobin is digested, this would still correspond to ∼1800 μg/ml, which is sufficient to block HSV-2 infection or bacterial growth entirely. These theoretical considerations are in line with experimental results obtained in previous studies ([@B41]; [@B71]) that revealed HBB(112--147) concentrations between 280 and 740 μg/g placenta tissue in different placenta samples, corresponding to an average concentration of 570 μg/g or ml. Thus, HBB(112--1476) may represent the AMP with the highest reported concentration in a human tissue and may play a key role in restricting transmission of viral and bacterial pathogens across the placenta and perhaps also other compartments.
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